International Journal of Hematology

, Volume 78, Issue 5, pp 439–442 | Cite as

MLL/AF-1p Fusion in Therapy-Related Early Pre-B Acute Lymphoblastic Leukemia with t(1;11)(p32;q23) Translocation Developing in the Relapse Phase of Acute Promyelocytic Leukemia

  • Takayuki Tsujioka
  • Hideho Wada
  • Shunji Yamamori
  • Takemi Otsuki
  • Sinichiro Suemori
  • Toshinori Kondo
  • Hidekazu Nakanishi
  • Yoshimasa Suetsugu
  • Makoto Mikami
  • Takashi Sugihara
Case Report


We report the development of therapy-related early pre-B acute lymphoblastic leukemia in a patient administered a topoisomerase II inhibitor, etoposide, a consolidation therapy agent for acute promyelocytic leukemia. Our case is of interest because of simultaneous relapse of the original leukemia and onset of therapy-related leukemia and relatively rare t(1;11) (p32;q23) translocation with confirmedMLL/AF- 1p fusion. This case suggests that careful monitoring forMLL gene rearrangements is necessary after administration of topoisomerase II inhibitors.

Key words

Therapy-related AL MLL AF- 1p FISH 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bloomfield CD, Archer KJ, Mrozek K, et al. 11q23 balanced chromosome aberrations in treatment-related myelodysplastic syndromes and acute leukemia: report from an international workshop.Genes Chromosomes Cancer. 2002;33:362–378.CrossRefPubMedGoogle Scholar
  2. 2.
    Andersen MK, Christiansen DH, Jensen BA, Ernst P, Hauge G, Pedersen-Bjergaard J. Therapy-related acute lymphoblastic leukaemia withMLL rearrangements following DNA topoisomerase II inhibitors, an increasing problem: report on two new cases and review of the literature since 1992.Br J Haematol. 2001;114: 539–543.CrossRefPubMedGoogle Scholar
  3. 3.
    Young BD, Saha V. Chromosome abnormalities in leukaemia: the 11q23 paradigm.Cancer Surv. 1996;28:225–245.PubMedGoogle Scholar
  4. 4.
    Cimino G, Rapanotti MC, Sprovieri T, Elia L. ALL1 gene alterations in acute leukemia: biological and clinical aspects.Haematologica. 1998;83:350–357.PubMedGoogle Scholar
  5. 5.
    Martinelli G, Testoni N, Zinzani PL, Biondi A, Cimino G, Tura S. Therapy-related acute leukemia associated with involvement of 11q23 after high grade non-Hodgkin lymphoma.Haematologica. 1998;83:283–284.PubMedGoogle Scholar
  6. 6.
    Dann EJ, Rowe JM. Biology and therapy of secondary leukaemias.Best Pract Res Clin Haematol. 2001;14:119–137.CrossRefPubMedGoogle Scholar
  7. 7.
    Takeyama K, Seto M, Uike N, et al. Therapy-related leukemia and myelodysplastic syndrome: a large-scale Japanese study of clinical and cytogenetic features as well as prognostic factors.Int J Hematol. 2000;71:144–152.PubMedGoogle Scholar
  8. 8.
    Pui CH, Chessells JM, Camitta B, et al. Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements.Leukemia. 2003;17:700–706.CrossRefPubMedGoogle Scholar
  9. 9.
    Sano K. Structure of AF3p21, a new member of mixed lineage leukemia(MLL) fusion partner proteins-implication forMLL-induced leukemogenesis.Leuk Lymphoma. 2001;42:595–602.CrossRefPubMedGoogle Scholar
  10. 10.
    Watanabe N, Kobayashi H, Ichiji O, et al. Cryptic insertion and translocation or nondividing leukemic cells disclosed by FISH analysis in infant acute leukemia with discrepant molecular and cytogenetic findings.Leukemia. 2003;17:876–882.CrossRefPubMedGoogle Scholar
  11. 11.
    Hayashi Y, Raimondi SC, Behm FG, et al. Two karyotypically independent leukemic clones with the t(8;21) and 11q23 translocation in acute myeloblastic leukemia at relapse.Blood. 1989;73: 1650–1655.PubMedGoogle Scholar
  12. 12.
    Taki T, Ohnishi H, Shinohara K, et al. AF17q25, a putative septin family gene, fuses the MLL gene in acute myeloid leukemia with t(11;17)(q23;q25).Cancer Res. 1999;59:4261–4265.PubMedGoogle Scholar
  13. 13.
    Mathew S, Head D, Rubnitz JE, Raimondi SC. Concurrent translocations of MLL and CBFA2 (AML1) genes with new partner breakpoints in a child with secondary myelodysplastic syndrome after treatment of acute lymphoblastic leukemia.Genes Chromosomes Cancer. 2000;28:227–232.CrossRefPubMedGoogle Scholar
  14. 14.
    Sawada H, Morimoto H, Wake A, Yamasaki Y, Izumi Y. Therapy- related acute myeloid leukemia with t(10;11)(q23;p15) following successful chemotherapy for acute promyelocytic leukemia with t(15;17)(q22;q21).Int J Hematol. 1999;69:270–271.PubMedGoogle Scholar
  15. 15.
    Rogaia D, Grignani F, Carbone R, et al. The localization of the HRX/ALL1 protein to specific nuclear subdomains is altered by fusion with its eps15 translocation partner.Cancer Res. 1997;57: 799–802.PubMedCentralPubMedGoogle Scholar
  16. 16.
    Gallagher RE. Retinoic acid resistance in acute promyelocytic leukemia.Leukemia. 2002;16:1940–1958.CrossRefPubMedCentralPubMedGoogle Scholar
  17. 17.
    Dombret H, Fenaux P, Soignet SL, Tallman MS. Established practice in the treatment of patients with acute promyelocytic leukemia and the introduction of arsenic trioxide as a novel therapy.Semin Hematol. 2002;39:8–13.CrossRefPubMedCentralPubMedGoogle Scholar
  18. 18.
    Degos L, Wang ZY. All trans retinoic acid in acute promyelocytic leukemia.Oncogene. 2001;20:7140–7145.CrossRefPubMedCentralPubMedGoogle Scholar
  19. 19.
    Fenaux P, Chomienne C, Degos L. Treatment of acute promyelocytic leukaemia.Best Pract Res Clin Haematol. 2001;14:153–174.CrossRefPubMedCentralPubMedGoogle Scholar
  20. 20.
    Bernard OA, Mauchauffe M, Mecucci C, Van den Berghe H, Berger R. A novel gene,AF-1p, fused to HRX in t(1;11)(p32;q23), is not related to AF-4, AF-9 nor ENL.Oncogene. 1994;9:1039–1045.PubMedGoogle Scholar
  21. 21.
    Confalonieri S, Di Fiore PP. The Eps15 homology (EH) domain.FEBS Lett. 2002;513:24–29.CrossRefPubMedGoogle Scholar
  22. 22.
    Waterman H, Yarden Y. Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases.FEBS Lett. 2001;490:142–152.CrossRefPubMedGoogle Scholar
  23. 23.
    Santolini E, Salcini AE, Kay BK, Yamabhai M, Di Fiore PP. The EH network.Exp Cell Res. 1999;253:186–209.CrossRefPubMedGoogle Scholar
  24. 24.
    Salcini AE, Chen H, Iannolo G, De Camilli P, Di Fiore PP. Epidermal growth factor pathway substrate 15, Eps15.Int J Biochem Cell Biol. 1999;31:805–809.CrossRefPubMedGoogle Scholar
  25. 25.
    Marsh M, McMahon HT. The structural era of endocytosis.Science. 1999;285:215–220.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2003

Authors and Affiliations

  • Takayuki Tsujioka
    • 1
  • Hideho Wada
    • 1
  • Shunji Yamamori
    • 2
  • Takemi Otsuki
    • 3
  • Sinichiro Suemori
    • 1
  • Toshinori Kondo
    • 1
  • Hidekazu Nakanishi
    • 1
  • Yoshimasa Suetsugu
    • 1
  • Makoto Mikami
    • 1
  • Takashi Sugihara
    • 1
  1. 1.Division of Hematology, Department of MedicineKawasaki Medical SchoolOkayamaJapan
  2. 2.Mitsubishi Kagaku Bio-clinical LaboratoriesTokyoJapan
  3. 3.Department of HygieneKawasaki Medical SchoolOkayamaJapan

Personalised recommendations